Abstract |
OSCC ( oral squamous cell carcinoma) is the most common oral malignancy and is estimated to affect approx. 350000 new patients worldwide this year. OSCC is characterized by a high degree of morbidity and mortality, as most patients exhibit local, regional and distant metastasis at the time of diagnosis. Recent genome-wide screening efforts have identified the serine proteinase uPA (urinary-type plasminogen activator, also known as urokinase) as a strong biomarker for prediction of poor disease outcome and a key candidate for molecular classification of oral neoplasms using a 'gene signature' approach. The proteinase uPA binds a surface-anchored receptor designated uPAR (uPA receptor), focalizing proteolytic activity to the pericellular milieu. Furthermore, uPA-uPAR can interact with transmembrane proteins to modify multiple signal transduction pathways and influence a wide variety of cellular behaviours. Correlative clinical data show elevated uPA-uPAR in oral tumour tissues, with tumours exhibiting high levels of both uPA and uPAR as the most invasive. Combined in vitro, pre-clinical and clinical data support the need for further analysis of uPA-uPAR as a prognostic indicator as well as a potential therapeutic target in OSCC.
|
Authors | Zonggao Shi, M Sharon Stack |
Journal | The Biochemical journal
(Biochem J)
Vol. 407
Issue 2
Pg. 153-9
(Oct 15 2007)
ISSN: 1470-8728 [Electronic] England |
PMID | 17880283
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Chemical References |
- PLAUR protein, human
- Receptors, Cell Surface
- Receptors, Urokinase Plasminogen Activator
- Urokinase-Type Plasminogen Activator
|
Topics |
- Carcinoma, Squamous Cell
(etiology, pathology)
- Humans
- Mouth Neoplasms
(etiology, pathology)
- Receptors, Cell Surface
- Receptors, Urokinase Plasminogen Activator
- Signal Transduction
- Urokinase-Type Plasminogen Activator
(physiology)
|